Hepatic Cytochrome P 450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats

  2008cited by this paper
• Metabolic Syndrome is Related to Nonalcoholic Steatohepatitis in Severely Obese Subjects

  2008cited by this paper
• Inhibition and induction of human cytochrome P450 enzymes: current status

  2008cited by this paper
• Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

  2008cited by this paper
• The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis.

  2008influential reference
• Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure.

  2008cited by this paper
• Microarray analysis of hepatic gene expression in pyrazole-mediated hepatotoxicity: identification of potential stimuli of Cyp2a5 induction.

  2008cited by this paper
• Cytochrome p450 and chemical toxicology.

  2008cited by this paper
• Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis

  2007cited by this paper
• Is the hypoxia-inducible factor-1 alpha mRNA expression activated by ethanol-induced injury, the mechanism underlying alcoholic liver disease?

  2006cited by this paper
• Liver disease selectively modulates cytochrome P450–mediated metabolism

  2006influential reference
• [Effects of chronic HBV infection on human hepatic cytochrome P450 3A4].

  2006cited by this paper
• Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study

  2005cited by this paper
• In Vivo Metabolic Activity of CYP2C19 and CYP3A in Relation to CYP2C19 Genetic Polymorphism in Chronic Liver Disease

  2005cited by this paper
• Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis

  2005influential reference
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma.

  2005cited by this paper
• Cytochrome P450 and liver diseases.

  2004influential reference
• Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.

  2004cited by this paper
• Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients.

  2004cited by this paper
• Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis

  2004cited by this paper
• The epidemiology of fatty liver

  2004cited by this paper
• Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases

  2003cited by this paper
• Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia.

  2003cited by this paper
• Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression.

  2003cited by this paper
• UDP glucuronosyltransferase mRNA levels in human liver disease.

  2002cited by this paper
• The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans.

  2002cited by this paper
• Polymorphisms of CYP2A6 and its practical consequences.

  2001cited by this paper
• Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis.

  2001influential reference
• Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.

  2000influential reference
• Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis

  1998cited by this paper
• Overexpression of Cytochrome P-450 Isoforms Involved in Aflatoxin B1 Bioactivation in Human Liver with Cirrhosis and Hepatitis

  1996cited by this paper
• Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease

  1995cited by this paper
• Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis.

  1995cited by this paper
• Extrahepatic Metabolism of Drugs in Humans

  1994cited by this paper
• CYP3A gene expression in human gut epithelium.

  1994cited by this paper
• Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity.

  1994cited by this paper
• Comparison of levels of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples.

  1993cited by this paper
• The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature

  1993cited by this paper
• The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease

  1992cited by this paper
• Spectroscopic quantitation of cytochrome P-450 in human lung microsomes.

  1990cited by this paper
• Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples.

  1990cited by this paper
• A Wilcoxon-type test for trend.

  1985influential reference

• Portal hypertension in NASH : is it different from other aetiologies?

  2023cites this paper
• Hepatic drug-metabolizing enzymes and drug transporters in Wilson’s disease patients with liver failure

  2021cites this paper
• Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity

  2021cites this paper
• Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip

  2021cites this paper
• PHARMACOKINETICS OF ANTI-BACTERIAL PREPARATIONS IN CYSTIC FIBROSIS IN CHILDREN

  2019influential citation
• Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation

  2018influential citation
• Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors

  2017cites this paper
• Methyl donor deficient diets cause distinct alterations in lipid metabolism but are poorly representative of human NAFLD

  2017cites this paper
• Human Primary Hepatocytes – Product Overview

  2017cites this paper
• Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.

  2016cites this paper
• ISSN 2320-5407 International Journal of Advanced Research (2016), Volume 4, Issue 1, 588- 605

  2016cites this paper
• Individualized medicine enabled by genomics in Saudi Arabia

  2015cites this paper
• Significantly Decreased and More Variable Expression of Major CYPs and UGTs in Liver Microsomes Prepared from HBV-Positive Human Hepatocellular Carcinoma and Matched Pericarcinomatous Tissues Determined Using an Isotope Label-free UPLC-MS/MS Method

  2015cites this paper
• Special Section on Transporters in Toxicity and Disease Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models s

  2014cites this paper
• Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models

  2014cites this paper
• Special Section on Transporters in Toxicity and Disease Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models s

  2014cites this paper
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin

  2013cites this paper
• Drug disposition in pathophysiological conditions.

  2012cites this paper
• Polychlorinated Biphenyls, Lead, and Mercury Are Associated with Liver Disease in American Adults: NHANES 2003–2004

  2010cites this paper
• Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease

  2010cites this paper
• Pregnane X Receptor and Constitutive Androstane Receptor at the Crossroads of Drug Metabolism and Energy Metabolism

  2010cites this paper
• Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation

  2010cites this paper
• Recent advances in nonalcoholic fatty liver disease

  2010cites this paper
• Integrating In Vitro Sildenafil Metabolism into a Physiologically-Based Pharmacokinetic (PBPK) Model: Validating a Bottom-Up Modeling Approach

  2009cites this paper